Protagonist Therapeutics, Inc.
PTGX
$96.75
$4.394.75%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.44M | 4.71M | 5.55M | 28.32M | 170.64M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.44M | 4.71M | 5.55M | 28.32M | 170.64M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 7.44M | 4.71M | 5.55M | 28.32M | 170.64M |
| SG&A Expenses | 11.43M | 11.13M | 10.55M | 11.74M | 8.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.79M | 51.13M | 47.59M | 47.63M | 43.86M |
| Operating Income | -50.36M | -46.42M | -42.04M | -19.31M | 126.78M |
| Income Before Tax | -43.72M | -39.34M | -34.60M | -11.66M | 133.66M |
| Income Tax Expenses | 666.00K | -- | 172.00K | -- | 1.99M |
| Earnings from Continuing Operations | -44.38M | -39.34M | -34.77M | -11.66M | 131.67M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.38M | -39.34M | -34.77M | -11.66M | 131.67M |
| EBIT | -50.36M | -46.42M | -42.04M | -19.31M | 126.78M |
| EBITDA | -49.98M | -46.06M | -41.74M | -19.07M | 126.90M |
| EPS Basic | -0.69 | -0.62 | -0.55 | -0.19 | 2.11 |
| Normalized Basic EPS | -0.43 | -0.39 | -0.34 | -0.12 | 1.34 |
| EPS Diluted | -0.70 | -0.62 | -0.55 | -0.19 | 1.99 |
| Normalized Diluted EPS | -0.43 | -0.39 | -0.34 | -0.12 | 1.26 |
| Average Basic Shares Outstanding | 64.03M | 63.77M | 63.51M | 62.96M | 62.33M |
| Average Diluted Shares Outstanding | 64.03M | 63.77M | 63.51M | 62.96M | 66.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |